Seaport Therapeutics, a clinical-stage biopharmaceutical company based around a unique drug delivery platform originally developed by Monash University researchers, has announced the closing of a $100 million oversubscribed Series A financing round.
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next month NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing